Amrutanjan Health Care has announced its audited financial results for the quarter and year ended March 31, 2026, following a Board meeting held on May 8, 2026. The company reported a year-on-year increase in profitability, with total income for the fiscal year rising to INR 52,012.66 lakhs from INR 46,949.50 lakhs in the previous year.

Financial Performance for FY26

For the full year ended March 31, 2026, the company recorded a profit after tax of INR 5,791.78 lakhs, compared to INR 5,083.47 lakhs in the prior year. Revenue from operations grew to INR 50,255.27 lakhs, up from INR 45,181.63 lakhs in FY25. Basic earnings per share (EPS) for the year improved to INR 20.03 from INR 17.58 in the previous year. The results include exceptional items, specifically a lease rent provision of INR 760.50 lakhs for the year.

The following table summarises the full-year financial performance:

Q4 Performance Highlights

For the quarter ended March 31, 2026, Amrutanjan Health Care delivered a strong operational performance. Revenue for the quarter stood at 1.5B Rupees, compared to 1.35B Rupees in the same quarter of the previous year. Profit after tax for the quarter was 161M Rupees versus 152M Rupees year-on-year. Notably, EBITDA for the quarter surged to 255M Rupees from 177M Rupees in the year-ago period, reflecting a significant improvement in operating efficiency. The EBITDA margin expanded to 17.05% from 13.07% year-on-year, underscoring improved cost management and operating leverage during the quarter.

The key Q4 metrics are presented below:

Business Update and Strategic Initiatives

The company reported double-digit growth in Pain Management and Women's Hygiene segments during FY 25-26, with the segment now renamed Women's Hygiene & Personal Care following the launch of new products. Brand Amrutanjan and Brand Comfy drove gross sales growth, with Comfy recording gross sales growth (before IND AS 115 adjustment) of 19% for FY26 and 22% in Q4. The XL variant's contribution to overall Comfy sales increased to 37% in FY 25-26 compared to 31% in the previous year. In Q4, the company launched new products in the Personal Care and Ortho Pain categories, including Women's Razors, Men's Razors, Antiseptic Plaster, Ortho Pain Oil, and Nasal Spray.

Advertisement spend for FY26 stood at Rs. 39 Cr against Rs. 33.92 Cr for FY25. Advertisement spend for Comfy was at Rs. 9.56 Cr for FY26 against Rs. 8.03 Cr for FY25. To expand rural market coverage, the company continued its Rural Van initiative across states including Uttar Pradesh, Tamil Nadu, Maharashtra, Gujarat, Madhya Pradesh, Chhattisgarh, Jharkhand, Andhra Pradesh, and Telangana. Marketing interventions included in-store activities for the Pain category across multiple states and a high-impact TV campaign for the Comfy brand.

The company also focused on expanding its sales and distribution network, with key operational metrics showing broad-based improvement during the year. The following table summarises the key sales and distribution metrics:

Management Commentary

The management noted that the team closed the year with exceptional delivery on operating profits, up by 34% before exceptional items, and top-line growth of 11%. Growth was witnessed across the Pain Management portfolio, particularly with LUP packs and premium formats. The company added 44,000 new chemists and plans to acquire 100,000 chemists by September of FY27. Exceptional items for the year included a one-time charge of INR 76MN in Q4 related to a legal case involving lease rent, and INR 12.5MN from the new Labour Code. The incremental impact of the new Labour Codes, consisting of gratuity and leave encashment benefits of INR 125.17 lakhs, primarily arose due to a change in wage definition.

Looking ahead, the company is confident about the demand environment and plans to relaunch its Congestion brand Relief. The management noted that COGS inflation is expected due to Middle East conflicts affecting crude prices and supply chains, which the company intends to mitigate through price increases to some extent. The new Sanitary Pad plant is slated to commence production in May, which is expected to improve the profitability of the Comfy brand. The company also noted that 68% of processes are digitized, with plans to reach 85% with the full implementation of DMS and SAP TM.

Dividend Declaration

The Board of Directors has recommended a final dividend of INR 2.90 per equity share for the financial year 2025-26. This dividend is applicable to 2,89,10,630 shares of INR 1 each fully paid up. If approved by shareholders at the Annual General Meeting, the dividend will be paid within 30 days of the meeting. An interim dividend of INR 1 per share was already paid during the quarter ended March 31, 2026.

Board Appointments and Approvals

In addition to the financial results, the board approved several key governance decisions in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Based on the recommendation of the Nomination and Remuneration Committee, Mr. Ramaswami Krishnan (DIN: 08562199) was appointed as an Additional Director designated as Non-Executive Independent Director for a period of five years effective from May 8, 2026, subject to shareholder approval. Mr. Krishnan is 65 years of age and holds qualifications as a CA, CS, and CWA, along with a Ph.D. and a Master's Degree in Business Administration. He was earlier associated with RSL Industries Limited and the Nagarjuna Group, and in his last assignment served as Director Finance & Marketing and Company Secretary at Malladi Drugs and Pharmaceuticals Limited. He is not related to any other directors of the company.

The board also approved the re-appointment of Mr. Muralidharan Swayambunathan (DIN: 09198315) as Non-Executive Independent Director for a second and final term of five consecutive years from June 29, 2026, subject to shareholder approval. Mr. Swayambunathan brings over 37 years of experience across industries in India and abroad, having worked with organisations including TVS Sundaram, Clayton Group Companies, and various international airports in India, as well as Jebel Ali Free Zone (JAFZA), Dubai. His expertise spans General Management, Finance, Corporate Governance, Secretarial, and Legal functions. He is not related to any other directors of the company.

The key details of both director appointments are summarised below:

Furthermore, the board approved the rollout of the revised Second Phase "ESOP 2" of the existing ESOP Scheme and appointed M/s. PKF Sridhar & Santhanam as Internal Auditors for the financial year 2026-2027.

Amrutanjan Health Care has added 44,000 new chemists to its distribution network, marking a significant milestone in the company's retail outreach efforts. The company has set a target of reaching 100,000 chemists by September FY27, underscoring its commitment to expanding its presence across pharmacy channels in India.

Distribution Expansion Milestone

The onboarding of 44,000 new chemists represents a substantial step in Amrutanjan Health Care's strategy to deepen its reach within the pharmaceutical retail ecosystem. By targeting 100,000 chemists by September FY27, the company aims to nearly double its current chemist network, broadening access to its product portfolio for consumers nationwide.

The following table summarizes the key parameters of this distribution initiative:

Strategic Significance

Expanding the chemist network is a critical component of over-the-counter and healthcare product distribution in India, where pharmacy outlets serve as primary points of consumer access. Amrutanjan Health Care's initiative to scale its chemist partnerships to 100,000 by September FY27 highlights the company's focus on strengthening last-mile distribution and improving product availability across geographies.